Elektrofi Secures $112 Million in Funding to Revolutionize Biologic Therapy Delivery

In an exciting development for the future of biopharmaceuticals, Elektrofi has successfully raised $112 million in its latest funding round, a testament to the growing confidence in its innovative platform.

Based in Boston, Elektrofi is at the forefront of biopharmaceutical formulation technology, committed to revolutionizing the way biologic therapies are delivered to patients.

With its proprietary Hypercon™ technology, Elektrofi addresses the critical limitations of traditional intravenous delivery by enabling patients to self-administer life-changing monoclonal antibodies and other large molecule drugs via convenient subcutaneous injections right from their homes.

This patient-centric approach not only enhances the quality of care but also improves adherence to treatment regimens, paving the way for a healthier world.

The newly acquired funding will primarily be allocated towards advancing the development and commercialization of its transformative therapies, as well as expanding partnerships with strategic collaborators.

With its significant capital infusion, Elektrofi is well-positioned to further innovate within the biopharmaceutical landscape, ensuring that patients have the flexibility and control they deserve in their healthcare journeys.

As Elektrofi continues to push the boundaries of biopharmaceutical technology, it remains committed to formulating the future of biologics, enhancing life for countless individuals in the process.

Visit www.Elektrofi.com to learn more about our mission and breakthroughs.